In this study, the aim was to develop NPs that reduce the activity of mTOR and AURORA pathways, potentially decreasing MYCN protein enhancement and stability, by combining inhibitors and targeting them specifically to the tumor, and to demonstrate their effect in NB. The gene discussed is MYCN; the disease is neoplasm.